Pharming N.V.(PHAR) - 2023 Q1 - Earnings Call Transcript

On the next slide, we can see sort of the treatment options that were available to manage these patients prior to the approval of Joenja in the U.S. On the one hand on the left, you can see it was limited to trying to address the immune deficiency, so using antibiotics to prevent infections, to treat infections, but also using immunoglobulin replacement therapy as a way to augment their own immune system. Next slide. And when we looked at the open-label data, what we saw is over time a reduction in the numb ...